Companies in #Complement-Mediated Diseases
Found 2 companies operating in this sector.
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing targeted C3 therapies to inhibit the complement cascade in diseases of hematology, ophthalmology, and nephrology. The company has two FDA-approved C3 inhibitors: Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre for geographic atrophy (GA) secondary to age-related macular degeneration.
Omeros Corporation is a Seattle-based biopharmaceutical company developing small-molecule and biologic therapies for complement-mediated diseases, immune-related disorders, and central nervous system conditions. Its first commercial product, Yartemlea (narsoplimab), is the first FDA-approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA) in hematopoietic stem cell transplantation.